NCT00914667

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Fesoterodine On The Pharmacokinetics And Pharmacodynamics Of A Single Supratherapeutic Dose Of Warfarin In Healthy Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.

Conditions

• Urinary Bladder, Overactive

Interventions

Type	Name	Description
DRUG	warfarin	Single Dose Warfarin 25 mg on Day 1
DRUG	Warfarin plus Fesoterodine	Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3

Timeline

• Start date: 2009-07-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2009-06-05
• Last updated: 2011-06-01

Locations

1 site across 1 country: United States